MX2023000868A - Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. - Google Patents

Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.

Info

Publication number
MX2023000868A
MX2023000868A MX2023000868A MX2023000868A MX2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A MX 2023000868 A MX2023000868 A MX 2023000868A
Authority
MX
Mexico
Prior art keywords
sulfur
preparation
method therefor
medical use
isoindoline derivative
Prior art date
Application number
MX2023000868A
Other languages
English (en)
Inventor
Feng He
Weikang Tao
Fanglong Yang
Gang Chen
Limin Zhang
Minqiang Jia
Peihua Guo
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023000868A publication Critical patent/MX2023000868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un derivado de isoindolina que contiene azufre ya un método de preparación del mismo y a su uso médico. En particular, la presente invención se refiere a un derivado de isoindolina que contiene azufre representado por la Formula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y su uso como agente terapéutico, en particular su uso como modulador de Cereblon. en el campo del tratamiento del mieloma múltiple. (ver Fórmula).
MX2023000868A 2020-07-20 2021-07-20 Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. MX2023000868A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010696995 2020-07-20
CN202010783483 2020-08-06
CN202011223930 2020-11-05
CN202110410441 2021-04-16
PCT/CN2021/107297 WO2022017365A1 (zh) 2020-07-20 2021-07-20 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2023000868A true MX2023000868A (es) 2023-02-22

Family

ID=79728998

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000868A MX2023000868A (es) 2020-07-20 2021-07-20 Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.

Country Status (11)

Country Link
US (1) US20230257366A1 (es)
EP (1) EP4183781A4 (es)
JP (1) JP2023534528A (es)
KR (1) KR20230042057A (es)
CN (1) CN115916768A (es)
AU (1) AU2021314401A1 (es)
BR (1) BR112023000817A2 (es)
CA (1) CA3184711A1 (es)
MX (1) MX2023000868A (es)
TW (1) TW202214594A (es)
WO (1) WO2022017365A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510766A (zh) 2022-01-19 2024-08-16 江苏恒瑞医药股份有限公司 一种含硫异吲哚啉类衍生物的晶型
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0518282A2 (pt) 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
CA2681633C (en) * 2007-03-20 2018-01-09 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
EP3106460B1 (en) 2010-02-11 2019-04-10 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
US11192898B2 (en) * 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
IL271889B2 (en) 2017-07-10 2023-03-01 Celgene Corp Antisplit compounds and methods of their use
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
SG11202011568XA (en) * 2018-05-23 2020-12-30 Celgene Corp Treating multiple myeloma and the use of biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)oxy)methyl)benzyl) piperazin-1-yl)-3-fluorobenzonitrile
JP7168773B2 (ja) 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
CA3155010A1 (en) * 2019-09-19 2021-03-25 The Regents Of The Universtiy Of Michigan Spirocyclic androgen receptor protein degraders

Also Published As

Publication number Publication date
WO2022017365A1 (zh) 2022-01-27
KR20230042057A (ko) 2023-03-27
AU2021314401A1 (en) 2023-03-09
CA3184711A1 (en) 2022-01-27
JP2023534528A (ja) 2023-08-09
EP4183781A4 (en) 2024-01-03
TW202214594A (zh) 2022-04-16
US20230257366A1 (en) 2023-08-17
BR112023000817A2 (pt) 2023-02-07
CN115916768A (zh) 2023-04-04
EP4183781A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
MX2023000868A (es) Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo.
MX2009008228A (es) N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide.
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2021011823A (es) Derivado pirroloheterociclico, metodo de preparacion del mismo y su aplicacion en medicina.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
MX2023005533A (es) Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
MX2023011166A (es) Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2022247920A9 (zh) 喹啉胺类化合物、其制备方法及其在医药上的应用
MX339096B (es) Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades.
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний